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Article

Chronic Kidney Disease Awareness Among Individuals
with Clinical Markers of Kidney Dysfunction
Delphine S. Tuot,*† Laura C. Plantinga,†‡ Chi-yuan Hsu,*† Regina Jordan,§ Nilka Ríos Burrows,§
Elizabeth Hedgeman, Jerry Yee,¶ Rajiv Saran, and Neil R. Powe,†‡ for the Centers for Disease Control Chronic
Kidney Disease Surveillance Team

Summary
Background and objectives Awareness of chronic kidney disease (CKD) among providers and patients is
low. Whether clinical cues prompt recognition of CKD is unknown. We examined whether markers of kidney disease that should trigger CKD recognition among providers are associated with higher individual
CKD awareness.
Design, setting, participants, & measurements CKD awareness was assessed in 1852 adults with an estimated GFR ⬍60 ml/min per 1.73 m2 using 1999 to 2008 National Health and Nutrition Examination Survey
data. CKD awareness was a “yes” answer to “Have you ever been told you have weak or failing kidneys?”
Participants were grouped by distribution of the following abnormal markers of CKD: hyperkalemia, acidosis, hyperphosphatemia, elevated blood urea nitrogen, anemia, albuminuria, and uncontrolled hypertension.
Odds of CKD awareness associated with each abnormal marker and groupings of markers were estimated
by multivariable logistic regression.
Results Among individuals with kidney disease, only those with albuminuria had greater odds of CKD
awareness (adjusted odds ratio, 4.0, P ⬍ 0.01) than those without. Odds of CKD awareness increased with
each additional manifested clinical marker of CKD (adjusted odds ratio, 1.3, P ⫽ 0.05). Nonetheless, 90% of
individuals with two to four markers of CKD and 84% of individuals with ⱖ5 markers of CKD were unaware of their disease.
Conclusions Although individuals who manifest many markers of kidney dysfunction are more likely to be
aware of their CKD, their CKD awareness remains low. A better understanding of mechanisms of awareness is required to facilitate earlier detection of CKD and implement therapy to minimize associated
complications.
Clin J Am Soc Nephrol 6: 1838 –1844, 2011. doi: 10.2215/CJN.00730111

Introduction
Chronic kidney disease (CKD) is a public health concern, affecting an estimated 13% of the US population
(1). Better management of CKD can slow progression
of renal dysfunction, prevent metabolic complications, and reduce cardiovascular-related outcomes
(2). Physician awareness of disease is critical for implementation of evidence-based therapies, and patient awareness is a major determinant of adherence
to those therapies.
Despite national efforts to heighten public concern
surrounding kidney disease (3), individual awareness
of CKD and its risk factors remains low (1,4 – 6). In the
1999 to 2004 National Health and Nutrition Examination Surveys (NHANES), only 8% and 41% of persons
with CKD stages III and IV, respectively, self-reported
their CKD (1). Similarly, only 9% of patients with
CKD and diabetes in a screening study were aware of
their CKD status (7), and only 5% of those with CKD
1838
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and coronary heart disease self-reported CKD awareness in a cohort study (8).
CKD awareness may be particularly important
among persons who exhibit clinical markers possibly
directly resulting from their renal dysfunction, because they would benefit from lifestyle and medical
interventions to enhance well-being. Wagner’s
Chronic Care Model (9), which posits an informed
patient and a prepared practice team produce productive interactions that lead to improved outcomes, offers one theoretical framework for how CKD awareness could arise. Thus, clinical markers of CKD
should trigger provider recognition of CKD and,
through patient-provider communication, increase individual awareness. Provider recognition has been
shown to be low (10), but prior studies have not
assessed whether providers are sensitive to other clinical cues that might help them recognize CKD.
We examined whether well-known manifestations
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of kidney disease were associated with greater individual
CKD awareness. We hypothesized that participants who
exhibited markers of kidney dysfunction for any given
level of estimated GFR (eGFR) were more likely to have a
provider who detected CKD and communicated the individual’s CKD status to the participant, resulting in greater
individual awareness of CKD.

Materials and Methods
Study Design
The NHANES is a continuous survey conducted by
the National Center for Health Statistics to examine
disease prevalence and trends in cross-sectional representative samples of noninstitutionalized US civilian
residents. The survey consists of a standardized in-home
interview and a physical examination/specimen collection
at a mobile examination center. All of the participants gave
informed consent. The protocol was approved by an institutional review board.
We examined data from the 1999 to 2008 NHANES (11).
The total number of adult nonpregnant NHANES study
participants with an eGFR of 15 to 59 ml/min per 1.73 m2
was 2375. Our sample included individuals who self-reported awareness or unawareness of CKD (n ⫽ 2365), had
complete laboratory data (n ⫽ 1932), and had seen a
health-care provider within the previous year (final n ⫽
1852). This ensured that participants had the opportunity
to develop CKD awareness.
Measurements
Self-reported sociodemographics (age, gender, race/ethnicity, marital status, social support, primary language,
education, and income), access to care (insurance and routine site for medical care), and diagnoses (CKD and diabetes) were obtained during interviews. BP was measured
during the examination; the mean of all measurements was
used. Serum potassium, serum bicarbonate, serum phosphate, blood urea nitrogen, and hemoglobin were measured using a Beckman Synchron LX20 analyzer from 1999
to 2007 and the Beckman Coulter UniCel DxC800 in 2008.
Serum creatinine was measured by the modified kinetic
method of Jaffe, and levels were corrected for different
analyzers (12,13). Random spot urine albumin and creatinine levels were measured using frozen specimens. Urine
albumin was measured using a solid-phase fluorescence
immunoassay; urine creatinine was measured using the
modified Jaffe kinetic method. Albuminuria and creatinine
were corrected according to NHANES documentation to
allow for comparison across all 10 years (13). Serum hemoglobin A1C was measured by an automatic high performance liquid chromatography system.
Definitions
The outcome variable was awareness of CKD. As in
prior studies, participants who responded “yes” to “Have
you ever been told by a doctor or other health professional
that you have weak or failing kidneys (excluding kidney
stones, bladder infections, or incontinence)?” during the
interview were defined as being aware of their CKD (1,7).
Predictors included common clinical markers of CKD:
hyperkalemia, metabolic acidosis, hyperphosphatemia, el-
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evated blood urea nitrogen (BUN), anemia, albuminuria,
and uncontrolled hypertension. Abnormal values were defined a priori as: serum potassium, ⬎5 mEq/L; serum bicarbonate, ⬍ 22 mEq/L; serum phosphate, ⬎4.5 mEq/L;
and BUN, ⬎15 mmol/L. Anemia was defined as a hemoglobin of ⬍12.5 g/dl in women and ⬍13.5 g/dl in men;
albuminuria was considered present at urinary albuminto-creatinine ratios of ⬎17 mg/g for men and ⬎25 mg/g
for women (14). Hypertension was considered uncontrolled if the average measurement of systolic or diastolic
BP was ⬎140 or ⬎90 mmHg, respectively. We created a
composite variable describing the number of manifest clinical markers of CKD, ranging from 0 to 7, consisting of
equally weighted binary indicators of the aforementioned
abnormal values. Categorization of this number was determined by distribution of clinical markers (zero to one
markers, two to four markers, and five to seven markers).
Diabetes was defined by self-report or a glycosylated hemoglobin of ⱖ6.5% (15).
Kidney disease was defined using single assessments of
eGFR, according to the Kidney Disease Outcomes Quality
Initiative staging guidelines (16). Estimated GFR was calculated according to the modified Modification of Diet in
Renal Disease Study equation for calibrated serum creatinine level (17).

Statistical Methods
Participant characteristics were compared by number of
abnormal clinical makers of CKD. Chi-squared and Wilcoxon rank-sum tests were used to evaluate associations
between number of abnormal markers and demographic
variables. Variance of proportions was estimated with Taylor series linearization. Multivariable logistic regression
was used to estimate the independent association between
CKD awareness and individual markers of CKD as well as
the overall burden of clinical markers of CKD. We adjusted
for characteristics that were shown or thought a priori to be
associated with clinical markers of CKD: age, gender, race/
ethnicity, education, income, eGFR, and presence of diabetes. To more closely mirror clinical practice, when clinical
markers of CKD may be obtained simultaneously with
eGFR (i.e. acidosis, hyperkalemia, and elevated BUN), we
also examined the association between each clinical marker
and CKD awareness without adjustment for eGFR.
Two sensitivity analyses were conducted. In the first,
percentiles of continuous predictor variables (rather than
binary indicators) were summed and equally weighted to
create a continuous composite variable, ranging from 0 to
100. This analysis ensured that any excess in odds of CKD
awareness was not due to inappropriate binary cutoff
points for the abnormal markers of CKD. In the second
analysis, eGFR was calculated according to the Chronic
Kidney Disease Epidemiology Collaboration equation (18),
which may more accurately estimate renal function at
higher levels of GFR. This was performed to ensure that
results were robust to the choice of eGFR estimating equation. All of the analyses were weighted to reflect the US
population, using STATA version 11 (StataCorp., College
Station, TX).

1840

Clinical Journal of the American Society of Nephrology

Results
Participant Characteristics and Burden of Abnormal
Clinical Markers of CKD
Among study participants, 40% had zero or one abnormal clinical markers of CKD, whereas only 2% displayed at
least five markers. Individuals with a greater number of
clinical markers were more likely than those with fewer
markers to be male, older than 60 years of age, and of
race/ethnicity other than non-Hispanic white (Table 1). In
addition, a greater number of clinical markers was significantly associated with lower yearly income (P trend ⬍
0.0001) and less social support (P trend ⬍ 0.03).
Included individuals were similar to those excluded because of no provider visit in the previous year, with respect
to age, race/ethnicity, social support, yearly income, and
access to health care (P ⬎ 0.05 for all). Additionally, compared with individuals who were excluded from the analysis because of missing awareness information, the study
population had a similar racial/ethnic minority distribution (P ⫽ 0.75). A broader definition of CKD including
albuminuria, however, would have included higher proportions of racial/ethnic minorities relative to the study
population (35% versus 15% nonwhite, P ⬍ 0.001).
In general, a greater burden of CKD markers was associated with lower eGFR (P ⬍ 0.001) (Figure 1). Among

study participants with an eGFR of 45 to 59 ml/min per
1.73 m2, 57% had zero to one clinical markers of CKD, and
1% had at least five markers. By contrast, among those
with an eGFR 15 to 29 ml/min per 1.73 m2, only 8% had
zero to one clinical markers of CKD, and 12% exhibited at
least five abnormal markers.

Association of Participant Awareness of CKD with Clinical
Markers of CKD
Among individuals with kidney disease, the majority of
whom had an eGFR between 30 and 59 ml/min per 1.73
m2, only 9% were aware of their renal dysfunction. Examination of the association between individual clinical markers of CKD and awareness of CKD revealed that albuminuria and hyperkalemia were both associated with greater
odds of CKD awareness (Table 2). However, independent
of eGFR, only albuminuria remained associated with increased odds of CKD awareness. Other common manifestations of CKD were not significantly associated with patient awareness of kidney dysfunction (Table 2).
Individuals who displayed a greater number of markers
of renal dysfunction had higher odds of being aware of
their kidney disease than individuals with kidney dysfunction who did not exhibit clinical markers. Individuals with

Table 1. Characteristics associated with abnormal clinical markers of CKD in the US population, NHANES 1999 to 2008

Number of Abnormal Clinical Markers of CKD
All
Total, n (%)
Mean estimated GFR ml/min per
1.73 m2 (SD)
Demographics, %
Male gender
Age
20 to 39 years
40 to 59 years
60 to 69 years
ⱖ70 years
Race/ethnicitya
non-Hispanic white
non-Hispanic black
Mexican American
Greater than high school education
Has social support
Currently married
Non-English language
Yearly family income
⬍$19,999
$20,000 to 44,999
$45,000 to 74,999
⬎$75,000
Access to health care, %
Has health insurance
Has a routine site for care
Comorbid conditions, %
Diabetes

1852
49.70 (8.41)

Zero to One

Two to Four

Five to Seven

772 (41.68%)
52.70 (6.60)

1048 (56.58%)
47.20 (10.12)

32 (1.73%)
33.38 (0)

P

⬍0.01
⬍0.01

38.22

31.13

44.98

45.51

4.13
20.95
18.81
56.11

5.70
27.39
19.52
47.40

2.60
14.70
18.29
64.41

3.52
18.40
12.57
65.51

85.68
6.55
1.93
74.37
94.61
61.82
2.76

90.68
3.19
1.22
81.54
95.27
67.48
1.99

80.84
9.70
2.56
67.38
92.27
56.69
3.54

83.31
12.33
4.35
72.55
77.57
45.69
1.85

27.76
33.65
21.81
16.92

21.37
30.20
26.91
21.52

33.42
36.83
17.23
12.52

52.06
32.97
4.63
10.34

96.28
97.49

95.34
97.25

97.14
97.66

98.21
100.00

0.14
0.70

22.09

13.01

30.26

49.82

⬍0.01

⬍0.01

⬍0.01
0.04
0.03
0.14
⬍0.01

Analyses have been weighted to reflect the US population. Total n ⫽ 1852 for all rows except education (n ⫽ 1847), social support
(n ⫽ 1726), marital status (n ⫽ 1813), language (n ⫽ 1813), income (n ⫽ 1681), insurance (n ⫽ 1839), and diabetes (n ⫽ 1851).
CKD, chronic kidney disease.
a
Individuals of “other” race/ethnicity not shown because of small sample size but are included in all analyses.
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Figure 1. | Percentage of individuals with clinical markers of
chronic kidney disease (CKD) by estimated GFR and number of
abnormal markers of CKD.

two to four clinical markers of CKD demonstrated 90%
greater odds of CKD awareness compared with those with
zero to one markers (adjusted odds ratio [AOR], 1.9; P ⫽
0.04). Participants who displayed at least five markers of
CKD demonstrated nonstatistically significant greater
odds of awareness (AOR, 3.6; P ⫽ 0.06) relative to participants with zero to one clinical markers of CKD. There was
a graded association between each additionally manifested clinical marker and awareness of CKD; this remained significant after adjustment for demographic
and socioeconomic factors and diabetes (Figure 2). Adjusting for eGFR mitigated the association.
Despite the positive association between an increasing
number of CKD clinical markers and individual awareness
of CKD, awareness of CKD among participants was very
low (Figure 3). Our model indicated that nearly 90% of
individuals with two to four markers of kidney disease
were unaware of their renal dysfunction, and among those
with at at least five markers of kidney disease, 84% were
unaware. These results remained consistent across all
NHANES study periods.
Sensitivity analyses using continuous predictor variables
rather than binary indicators and expanding the study
population to all individuals with an eGFR ⬍60 ml/min
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Figure 2. | Adjusted odds ratios and 95% confidence intervals of
CKD awareness associated with each additional clinical marker of
CKD. (Model 1) unadjusted. (Model 2) Model 1 ⫹ demographics
(age, gender, race/ethnicity, education). (Model 3) Model 2 ⫹ socioeconomic status (income). (Model 4) Model 3 ⫹ diabetes. (Model 5)
Model 4 ⫹ estimated GFR.

per 1.73 m2 regardless of whether they had seen a provider
within the previous year produced similar results (data not
shown). When the Chronic Kidney Disease Epidemiology
Collaboration estimating equation was used to determine
whether participants had kidney disease, no substantial
differences in association estimates were found (data not
shown).

Discussion
We demonstrated that individual awareness of CKD is
positively associated with a greater number of manifestations of renal dysfunction, independent of eGFR. Although
this association was expected, the high degree of CKD
unawareness among individuals with at least five markers
of their kidney disease and the persistence of unawareness
over time were not. Our study is consistent with previous
investigations demonstrating low levels of individual CKD
awareness (1,4,6) but highlights the profound lack of
awareness among individuals with an eGFR ⬍60 ml/min
per 1.73 m2 who have already developed either late complications of kidney disease (hyperkalemia, acidosis, and
hyperphosphatemia) or albuminuria, which are associated

Table 2. Odds ratios for awareness of CKD by abnormal levels of individual clinical markers of CKD in the US population, NHANES
1999 to 2008

Albuminuriac
Hyperkalemia (serum potassium, ⬎5.0 mEq/L)
Hyperphosphatemia (serum phosphorus, ⬎4.5 mEq/L)
Anemia (hemoglobin ⬍12.5 g/dl in women, 13.5 g/dl in men)
Acidosis (serum bicarbonate, ⬍22 mEq/L)
Elevated blood urea nitrogen (⬎15 mmol/L)
Uncontrolled hypertension (⬎140/⬎90 mmHg)

Odds Ratios for
Awareness
of CKD (95% CI)a

Odds Ratios for
Awareness of CKD,
Independent of estimated
GFR (95% CI)b

5.46 (3.10 to 9.60)
2.63 (1.32 to 5.18)
1.41 (0.67 to 2.95)
1.56 (0.98 to 2.50)
1.11 (0.72 to 1.72)
1.05 (0.58 to 1.90)
0.65 (0.26 to 1.67)

4.00 (2.11 to 7.39)
1.56 (0.86 to 2.83)
1.10 (0.54 to 2.26)
1.03 (0.59 to 1.81)
0.94 (0.60 to 1.45)
0.62 (0.30 to 1.23)
0.50 (0.14 to 1.78)

Analyses have been weighted to reflect the US population. CKD, chronic kidney disease; CI, confidence interval.
a
Adjusted for other manifestations listed and age, gender, race/ethnicity, education, income, and diabetes.
b
Adjusted for everything in previous model and estimated GFR.
c
Albuminuria is defined as urinary albumin-to-creatinine ratio ⬎17 mg/g in men and ⬎25 mg/g for women.
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Figure 3. | Adjusted percentage of chronic kidney disease (CKD)
awareness and unawareness by number of abnormal clinical markers of CKD. The values are adjusted for age, gender, race/ethnicity,
education, income, diabetes, and estimated GFR.

with poor outcomes in this patient population (19,20). Unlike individuals who may never experience sequelae of
their kidney disease, namely individuals with CKD defined solely by albuminuria and elderly patients with decreased eGFR from “natural aging” (21,22), patients who
exhibit complications from their renal dysfunction may
particularly benefit from being aware of their CKD.
Awareness of CKD is a necessary first step toward adopting lifestyle and risk-factor modifications necessary to prevent progression of kidney disease and to minimize adverse sequelae (23).
The mechanism behind individual awareness of CKD is
not understood. In this study, we illustrated that sociodemographic factors such as increased age, nonwhite race/
ethnicity, low income, and low levels of formal education
were independently associated with a greater burden of
abnormal markers of CKD, in addition to low CKD awareness. However, in our study, these factors did not significantly affect the association between an increasing number
of CKD markers and CKD awareness. The high percentage
of individuals with a routine site for medical care in our
study population may explain these results, because traditional demographic and socioeconomic factors associated
with poor CKD awareness may not play as large a role in
an established primary care provider relationship.
The large percentage of CKD unawareness among individuals with a greater number of clinical markers of kidney disease can be interpreted in a variety of ways. It is
possible that low individual awareness of CKD despite
multiple markers of kidney dysfunction reflects a low level
of provider testing for kidney disease or poor recognition
of kidney disease by clinicians. Low levels of CKD awareness among primary care providers have been documented (10,24,25); however, it is unlikely that clinician
unawareness of CKD could fully explain this degree of
patient unawareness of kidney disease. Ineffective communication by providers who appropriately recognize CKD
and its complications may also play a role. Provider time
constraints, clinician/patient language discordance, patient cognitive disabilities, and low patient health literacy
may all contribute to poor communication surrounding the

diagnosis of CKD. Lastly, our results could reflect flaws in
ascertainment of patient awareness of CKD.
Among the abnormal laboratory markers of CKD that
are often obtained simultaneously with eGFR, only hyperkalemia was associated with greater odds of CKD awareness. This can be explained by the frequent, although not
exclusive, presence of hyperkalemia in severe (rather than
moderate) kidney dysfunction and its association with potential life-threatening cardiovascular events. This association did not hold true when tested independently of
eGFR, however. Thus, it is possible that providers consider
some of the markers of CKD, such as anemia or acidosis, as
independent illnesses rather than markers of kidney disease. Interestingly, elevated BUN was not associated with
increased odds of CKD awareness. Elevated BUN is not
only a marker of CKD but also of dehydration and acute
kidney injury. Thus, although not assessed in this study, it
is plausible that elevated serum BUN levels are associated
with greater awareness of acute kidney injury rather than
CKD.
Among all of the common markers of CKD, only albuminuria was associated with greater odds of CKD awareness independent of eGFR. Educational efforts to increase
CKD awareness among the general public, such as formation of the National Kidney Disease Education Program by
the National Institutes of Health in 2001 (26) and dissemination of the Kidney Disease Outcomes Quality Initiative
staging (16), have focused on recognition of albuminuria as
a risk factor for CKD progression. Our results may reflect,
in part, the success of these programs and suggest that
educational programs should further emphasize other clinical manifestations of CKD as markers of advanced kidney
disease, irrespective of eGFR.
This study has several limitations. First, the cross-sectional nature of NHANES may lead to misclassification of
participants with CKD, because estimates of GFR and albuminuria were on the basis of single laboratory values. As
in other research endeavors (27,28), lack of longitudinal
data may have led to inclusion of individuals with acute
kidney injury and not CKD. Second, awareness is selfreported and is subject to recall bias. Third, it is possible
that the cutoffs used to define abnormal clinical markers of
CKD were not extreme enough to trigger clinician recognition of kidney dysfunction. However, these definitions of
abnormality were set a priori, and a sensitivity analysis
using continuous predictors rather than binary predictors
depicted similar associations between individual markers
of CKD and CKD awareness. Fourth, neither provider
factors associated with CKD awareness nor the communication process between providers and participants could
be assessed using these data. Provider understanding and
recognition of CKD, quality of provider-patient communication, and frequency of patient visits with the same health
care provider are likely determinants of patient understanding of CKD and would help frame our results.
In summary, despite efforts to increase CKD awareness
in the community, individuals with many complications of
their kidney dysfunction remain unaware of their disease.
Current educational efforts for primary care providers and
the general public should reinforce not only recognition of
CKD on the basis of eGFR and presence of albuminuria but
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also recognition of other common manifestations of
CKD. As a marker for increased risk of cardiovascular
and all-cause mortality, routine incorporation of CKD
into provider-patient communication and clinical decision-making for patients with clinical manifestations of
CKD is warranted. In addition, future research should
focus on better understanding the mechanisms of patient
awareness of CKD and the best metrics by which CKD
awareness can be measured. Examination of the effect of
patient health literacy and patient-provider communication on CKD awareness is necessary to determine optimal points of intervention to facilitate earlier recognition
of CKD, slow the progression of kidney disease, and
minimize associated complications.
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